To characterize cancer cell signatures in MBMs, we compared the expression of two established programs: the AXL-high program (associated with invasiveness and drug resistance) and the MITF-high program (defined by melanocyte lineage markers including MITF) [26,40,41]. The gene discussed is AXL; the disease is cancer.